Ligne de temps
01 janv. 2022
publication
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Lire plus16 déc. 2020
publication